Shengli Xue

National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University

Affiliated withThe First Affiliated Hospital of Soochow University

Research Area

Biography

Shengli Xue has not added Biography.
If you are Shengli Xue and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
[Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease]. Ai zheng = Aizheng = Chinese journal of cancer\| PubMed ID: 16965686	2006
CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. American journal of hematology\| PubMed ID: 17874449	2008
[A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 18681306	2008
[Surgical treatment and pathological findings of hematological malignancies patients complicated with lung diseases.]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 20193605	2009
Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo. Molecular biology reports\| PubMed ID: 21390503	2011
[Genetic diagnosis of a patient with non-syndromic variants of congenital neutropenia]. Zhonghua nei ke za zhi\| PubMed ID: 22333123	2011
[Diagnosis and treatment procedures of congenital neutropenia]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 23114152	2012
[Comparison of the biological characteristics of serum-free and fetal bovine serum-contained medium cultured umbilical cord-derived mesenchymal stem cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 23336223	2012
Interdigitating dendritic cell sarcoma presenting simultaneously with acute myelomonocytic leukemia: report of a rare case and literature review. International journal of hematology\| PubMed ID: 23605368	2013
Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study ... Hematological oncology\| PubMed ID: 23616245	2013
[IAG regimen for patients with refractory/relapsed acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 23906465	2013
Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Experimental and therapeutic medicine\| PubMed ID: 24137301	2013
[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 24171961	2013
[Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 24606651	2014
[Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myiloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 25916300	2015
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 26759101	2015
[Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 27014984	2016
Pulmonary mucormycosis: A case report and review of the literature. Oncology letters\| PubMed ID: 27123061	2016
Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. American journal of translational research\| PubMed ID: 27158357	2016
Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach. Scientific reports\| PubMed ID: 27941907	2016
FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation... International journal of hematology\| PubMed ID: 28616699	2017
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients. Hematology (Amsterdam, Netherlands)\| PubMed ID: 28876197	2018
Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion\| PubMed ID: 29075063	2017
Downregulation of HADH promotes gastric cancer progression via Akt signaling pathway. Oncotarget\| PubMed ID: 29100311	2017
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can ... Bone marrow transplantation\| PubMed ID: 29942002	2019
Effects of preemptive interferon-α monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study. Annals of hematology\| PubMed ID: 29995264	2018
Impact of -ITD length on prognosis of acute myeloid leukemia. Haematologica\| PubMed ID: 30076182	2019
Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer science\| PubMed ID: 30320942	2018
The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population. Clinical lymphoma, myeloma & leukemia\| PubMed ID: 30555035	2019
Clinical Features of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation Combined with Infusion of a Cord Blood. Stem cells and development\| PubMed ID: 30977441	2019
[Mutation Spectrum of FANCJ Gene in Adult Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 30998136	2019
Pretransplant FLT3-ITD levels predict outcome after allogeneic hematopoietic cell transplantation for AML patients in the first remission. Bone marrow transplantation\| PubMed ID: 31147598	2020
PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD acute myeloid leukemia. Blood\| PubMed ID: 31217189	2019
The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients. Clinical lymphoma, myeloma & leukemia\| PubMed ID: 32173273	2020
Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report. Biomarker research\| PubMed ID: 32399214	2020
Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor... Hematological oncology\| PubMed ID: 32710795	2020
Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Translational oncology\| PubMed ID: 32745961	2020
PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation. Bone marrow transplantation\| PubMed ID: 33214690	2021
Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia. Hematological oncology\| PubMed ID: 33521954	2021
Early T-Cell Precursor Acute Lymphoblastic Leukemia and T/Myeloid Mixed Phenotype Acute Leukemia Possess Overlapping Characteristics and Both Benefit From CAG-Like Regimens and Allogeneic He... Transplantation and cellular therapy\| PubMed ID: 33785365	2021
Correction to: PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation. Bone marrow transplantation\| PubMed ID: 33875816	2021
Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience. Haematologica\| PubMed ID: 34320787	2021
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leukemia & lymphoma\| PubMed ID: 34323656	2021
[Effect of FLT3-ITD Length on 32D Cell Proliferation, Apoptosis and Sensitivity to FLT3 Inhibitor]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 34362479	2021
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in oncology\| PubMed ID: 34540696	2021
A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports. Frontiers in oncology\| PubMed ID: 34956909	2021
The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Scientific reports\| PubMed ID: 35013456	2022
Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochemical and biophysical research communications\| PubMed ID: 35101664	2022
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells . Oncology reports\| PubMed ID: 35103292	2022
Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review. Clinical case reports\| PubMed ID: 35140963	2022
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment. Frontiers in oncology\| PubMed ID: 35211416	2022
Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine. OncoTargets and therapy\| PubMed ID: 35221695	2022
Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-2. Annals of hematology\| PubMed ID: 35235026	2022
Phosphoproteomics profiling reveals a kinase network conferring acute myeloid leukaemia intrinsic chemoresistance and indicates HMGA1 phosphorylation as a potential influencer. Clinical and translational medicine\| PubMed ID: 35297189	2022
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. Journal of hematology & oncology\| PubMed ID: 35365211	2022
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. Frontiers in immunology\| PubMed ID: 35371098	2022
Abnormal body composition related to the early clinical adverse outcome after HSCT. Bone marrow transplantation\| PubMed ID: 35461359	2022
[Observation of Nutritional Status Changes in Patients with Acute Leukemia During Chemotherapy]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 35981358	2022
Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric ... Frontiers in immunology\| PubMed ID: 36105799	2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. Frontiers in oncology\| PubMed ID: 36185253	2022
Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. American journal of hematology\| PubMed ID: 36219502	2023
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 36240005	2023
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematological oncology\| PubMed ID: 36251458	2023
CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymp... Bone marrow transplantation\| PubMed ID: 36253466	2023
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis. Annals of hematology\| PubMed ID: 36394582	2023
[Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 36476881	2022
Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report. Clinical case reports\| PubMed ID: 36619491	2023
Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia. Annals of hematology\| PubMed ID: 36745193	2023
Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood advances\| PubMed ID: 36897251	2023
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leukemia & lymphoma\| PubMed ID: 36964663	2023
Metagenomic next-generation sequencing performed on blood samples for the early recognition of severe Pneumocystis pneumonia in critical hematological patients. Medicine\| PubMed ID: 37026960	2023
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal\| PubMed ID: 37095120	2023
Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Annals of hematology\| PubMed ID: 37103615	2023
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL. Blood cancer journal\| PubMed ID: 37137904	2023
Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration. Frontiers in immunology\| PubMed ID: 37143650	2023
Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia. British journal of haematology\| PubMed ID: 37144604	2023
CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months. Blood cancer journal\| PubMed ID: 37164955	2023
Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology (Amsterdam, Netherlands)\| PubMed ID: 37191301	2023
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of hematology\| PubMed ID: 37227492	2023
The Use of SARS-CoV-2-Positive Donors in Hematopoietic Stem Cell Transplantation. Transplantation proceedings\| PubMed ID: 37236865	2023
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. British journal of haematology\| PubMed ID: 37246158	2023
Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3-4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021... Bone marrow transplantation\| PubMed ID: 37253803	2023
The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation... Annals of hematology\| PubMed ID: 37301787	2023
Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias. Hematology (Amsterdam, Netherlands)\| PubMed ID: 37477259	2023
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood\| PubMed ID: 37478399	2023
Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Molecular carcinogenesis\| PubMed ID: 37555764	2023
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood cancer journal\| PubMed ID: 37821435	2023
CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet rec... Clinical and translational medicine\| PubMed ID: 37882317	2023
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood cancer journal\| PubMed ID: 38012154	2023
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. Clinical case reports\| PubMed ID: 38084356	2023
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia. British journal of haematology\| PubMed ID: 38180132	2024
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study. Blood cancer journal\| PubMed ID: 38238305	2024
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Stem cell research & therapy\| PubMed ID: 38282037	2024
Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia. Annals of hematology\| PubMed ID: 38381173	2024
Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia. HemaSphere\| PubMed ID: 38435426	2024
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study. Leukemia research\| PubMed ID: 38493755	2024
Clonal evolution from B-cell acute lymphoblastic leukemia with <I>BCR::ABL1</I> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell t... Haematologica\| PubMed ID: 38961741	2024
Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements. Annals of hematology\| PubMed ID: 38990294	2024
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease. Blood cancer journal\| PubMed ID: 39179531	2024
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based ... Blood cancer journal\| PubMed ID: 39179571	2024
Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia. HemaSphere\| PubMed ID: 39380843	2024
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation. Journal of hematology & oncology\| PubMed ID: 39396017	2024
Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of hematology\| PubMed ID: 39400743	2024
Corrigendum to "The Use of SARS-CoV-2-Positive Donors in Hematopoietic Stem Cell Transplantation" [Transplant Proc, 2023. 55(8): p. 1810-1814.]. Transplantation proceedings\| PubMed ID: 39489655	2024
Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations. Bone marrow transplantation\| PubMed ID: 39658655	2025
Chidamide combined with azacitidine as a novel double epigenetic preemptive treatment for a myelodysplastic syndrome patient showing molecular relapse after allogeneic hematopoietic stem cel... Annals of hematology\| PubMed ID: 39668198	2024
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma. Annals of hematology\| PubMed ID: 39692783	2025
Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed acute myeloid leukemia. Haematologica\| PubMed ID: 39973368	2025
Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 40008901	2025
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood\| PubMed ID: 40009498	2025
Mendelian randomization reveals causal effect of Hashimoto's thyroiditis on immune thrombocytopenic purpura. Hematology (Amsterdam, Netherlands)\| PubMed ID: 40173418	2025
[Clinical Characteristics of Acute Leukemia Patients with Fusion Gene Positivity and Prognostic Analysis of Combined Venetoclax Targeted Therapy]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 40613160	2025
The Application of Personalized Conditioning Regimens in Relapsed/Refractory Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation proceedings\| PubMed ID: 40947356	2025
Developing a Framework of Entrustable Professional Activities for Residency Training in Hematology. Advances in medical education and practice\| PubMed ID: 40955302	2025
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-mat... Leukemia & lymphoma\| PubMed ID: 41048093	2025
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT. Clinical epigenetics\| PubMed ID: 41084078	2025
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial. Blood cancer journal\| PubMed ID: 41145445	2025
A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Phi... Cancer\| PubMed ID: 41199560	2025
The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy. British journal of haematology\| PubMed ID: 41224498	2025
[A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 41234101	2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study... Haematologica\| PubMed ID: 41307138	2025
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology\| PubMed ID: 41338863	2025